MedTrace Logo

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

NCT01437618 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2011-09-21

No results posted yet for this study

Summary

The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of BRAF mutant metastatic colorectal cancer patients

Conditions

Interventions

DRUG

FOLFOXIRI plus bevacizumab

* BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by * IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by * OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with * l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by * 5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks

Sponsors & Collaborators

  • Azienda Ospedaliero, Universitaria Pisana

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Completion
2011-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01437618 on ClinicalTrials.gov